breast cancer
Conditions
Interventions
Obtain consent from patients who have been diagnosed with breast cancer. After consent is obtained, treatment will be performed according to the treatment plan. Study subjects who will receive neoadju
Sponsors
Koizumi Kei
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Female patients age 20 or older 2.Patients with an initial diagnosis of primary breast cancer (including bilateral breast cancer) 3 Patients scheduled neoadjuvant chemotherapy or endocrine therapy 4.Patients whose consent for this study has been obtained by signing the consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with photosensitivity 2.Patients who cannot keep the same posture for the measurement time (about 40 minutes) 3.Patients with obvious distant metastasis (lung metastasis, liver metastasis, bone metastasis, etc.) 4.Patients with recurrent breast cancer 5.Patients who are judged by the principal investigator (or sub-investigator) to be in a condition inappropriate for the participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Longitudinal changes in optical data before neoadjuvant therapy and at early point of treatment, and changes in tumor size due to the therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between optical data and MRI/CT and pathological results Adverse events Device deficiencies | — |
Contacts
Public ContactNobuko Yoshizawa
Hamamatsu University Hospital
Outcome results
None listed